Clinical response associated with radiographic regression of a cervicomedullary ependymoma in a NF2 patient treated by bevacizumab.
Department of Neurosurgery, Neurofibromatosis type 2 Clinic of Ile de France, Neurofibromatosis Reference Center, Pitié-Salpêtrière Hospital, AP-HP, 75013, Paris, France.|Université Paris 6 Pierre et Marie Curie, 75013, Paris, France.
W I
WI
Essayed
Department of Oncology, La Rochelle-Re-Aunis Hospital, 17019, La Rochelle, France.
A
A
Bernard
Department of Neurosurgery, Neurofibromatosis type 2 Clinic of Ile de France, Neurofibromatosis Reference Center, Pitié-Salpêtrière Hospital, AP-HP, 75013, Paris, France. michel.kalamarides@aphp.fr.|Université Paris 6 Pierre et Marie Curie, 75013, Paris, France. michel.kalamarides@aphp.fr.
M
M
Kalamarides
D000328:Adult; D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D000068258:Bevacizumab / Q000627:therapeutic use*; D004806:Ependymoma / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy; D005260:Female; D006801:Humans; D008279:Magnetic Resonance Imaging; D016518:Neurofibromatosis 2 / Q000150:complications / Q000188:drug therapy*; D011859:Radiography; D013120:Spinal Cord Neoplasms / Q000150:complications / Q000000981:diagnostic imaging / Q000188:drug therapy
D020533:Angiogenesis Inhibitors; D000068258:Bevacizumab